ResMed (RMD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

ResMed

NYSE•Healthcare•Medical Instruments & Supplies

$228.42+0.17(<0.01%)After hours

Market Cap

$32.64B

P/E

21.4x

P/S

5.8x

P/B

5.0x

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

How this company scores

ExcellentMetricSide Score: 80/100

Strongest: Profitability (22/25); weakest: Cash & Earnings Quality (18/25).

Profitability22/25

Growth19/25

Balance Sheet & Red Flags21/25

Cash & Earnings Quality18/25

Strengths

Strong marginsHigh ROELow leverageCash-backed earnings

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 21.4x5y range 21.0x – 77.4x

Currently below its 20-quarter median.

P/S · 5.8x5y range 5.0x – 11.5x

Currently near its 20-quarter median.

P/B · 5.0x5y range 4.9x – 12.8x

Price & Volume

Market Cap $32.64B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $5.65B
Q. Revenue: $1.46B
TTM EBITDA: $2.09B
TTM Op. Income: $1.89B
Q. Op. Income: $448.71M
TTM Net Income: $1.52B
Q. Net Income: $383.43M
EPS: $2.649
Shares Out.: $144.73M

$5.65B in TTM revenue grew 9.9% YoY, reaching $1.46B last quarter. TTM EBITDA of $2.09B and TTM operating income of $1.89B show growth is flowing through to the bottom line. TTM net income of $1.52B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 58.8%
EBITDA Margin: 33.7%
Op. Margin: 30.7%
Net Margin: 26.2%

Op. margin of 30.7% is down 3.1% YoY — costs are rising relative to revenue. Net margin at 26.2% and gross margin of 58.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 9% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 21.4x
P/S Ratio: 5.8x
P/B Ratio: 5.0x

At 21.4x P/E, the stock trades within typical market levels. P/S of 5.8x and P/B of 5.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 21% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $8.97B
Cash: $1.47B
Long-Term Debt: $399.42M
Book Value: $6.59B
D/E Ratio: 0.1
Debt/EBITDA: 0.8

With $8.97B in assets and $399.42M in long-term debt, D/E is 0.1and book value is $6.59B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 7 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $454.63M
TTM Free Cash Flow: $1.65B
FCF Margin: 29.2%
FCF / Net Income: 1.1

TTM FCF of $1.65B on $454.63M in operating cash flow. The FCF / Net Income ratio of 1.1x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.